Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Parallel Study to Investigate Dopaminergic D2 and Serotoninergic 5HT2A Receptor Occupancy at Stable Plasma Concentrations of SB-773812 After Repeated Doses in Schizophrenic Patients. Relationship With Pharmacokinetics and Efficacy Readouts.

NCT00269035 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00269035
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00269035 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Parallel Study to Investigate Dopaminergic D2 and Serotoninergic 5HT2A Receptor Occupancy at Stable Plasma Concentrations of SB-773812 After Repeated Doses in Schizophrenic Patients. Relationship With Pharmacokinetics and Efficacy Readouts.
Lead sponsor
GlaxoSmithKline
Phase
Phase 1
Overall status
Completed
Start date
June 21, 2005
Completion date
May 26, 2007
Enrollment
95 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia